https://www.bioworld.com/rss en-us Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732621 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732621-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system While biomedical resources in the form of specialized tools, hundreds of thousands of published papers and huge repositories of ‘omics, health records and other data, are growing exponentially, discovery is getting slower and more expensive. That is the perspective from which scientists at Stanford University approached the development of their artificial intelligence (AI) research assistant Biomni. http://www.bioworld.com/articles/732561 Thu, 09 Jul 2026 14:00:00 -0400 https://www.bioworld.com/articles/732561-ai-co-scientist-performs-biomedical-research-at-expert-level-in-less-time Data flow concept Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development, according to presentations at the FENS Forum 2026. http://www.bioworld.com/articles/732497 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732497-fens-2026-next-gen-biologics-take-on-brain-disease Silhouette with keyhole At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience meeting – a symposium on ectodomain shedding showcased how soluble synaptic proteins are emerging as both biomarkers and therapeutic candidates for disorders ranging from autism to schizophrenia. http://www.bioworld.com/articles/732479 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732479-fens-2026-shedding-light-on-the-sheddome Art concept for medical research Astrazeneca plc has returned to China’s CSPC Pharmaceutical Group Ltd. for another discovery collaboration, this time in a deal worth up to $1.77 billion to use CSPC’s siRNA drug discovery platform and extrahepatic targeted delivery technology to develop small nucleic acid drug candidates. http://www.bioworld.com/articles/732396 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732396-astrazeneca-returns-to-tap-chinas-cspc-in-17b-discovery-deal Deal illustration The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly, researchers are suspecting that such epilepsies share mechanisms with dementia. Summarizing the highlights of epilepsy research presented at the recent Annual Congress of the European Academy of Neurology (EAN), Aleksandar Ristic told his audience that the biggest epilepsy story out of the Congress was “not a drug, but it was a reframing.” http://www.bioworld.com/articles/732395 Mon, 06 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732395-hyperexcitability-may-be-joint-problem-in-epilepsy-dementia Illustration of brain and brain waves, concept of focal seizure Two papers published in the July 1, 2026, issues of Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types. Nature and Nature Cancer have reported on preclinical and early clinical data with glycoprotein nonmetastatic melanoma protein B (GPNMB)-targeting CAR T cells in two separate solid tumor types.]]> http://www.bioworld.com/articles/732356 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732356-with-gpnmb-car-t-makes-further-inroads-in-solid-tumors Illustration of CAR T Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill patients have received an implant to treat Parkinson’s disease, which is DBS’ greatest success story. http://www.bioworld.com/articles/732241 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732241-deep-brain-stimulation-from-the-shallows-tomorrows-bci-technology Black wavy lines forming an abstract sound wave.png The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732354 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732354-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732204 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732204-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. http://www.bioworld.com/articles/732184 Wed, 24 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732184-pulmonary-inflammation-unveils-three-severe-pneumonia-subtypes Lungs anatomy MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732152 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732152-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Researchers at the Wyss Institute of Harvard University have used a mix of machine learning and classical screening techniques to identify small molecules that were effective against Neisseria gonorrhoeae in vagina-on-a-chip and mouse models of infection. Their findings were published in the June 17, 2026, issue of Science Translational Medicine. Neisseria gonorrhoeae in vagina-on-a-chip and mouse models of infection. Their findings were published in the June 17, 2026, issue of Science Translational Medicine.]]> http://www.bioworld.com/articles/732151 Tue, 23 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732151-going-after-gonorrhea-with-artificial-intelligence Illustration of Neisseria gonorrhoeae More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural signals are increasingly moving from labs to real-world settings to test their potential to treat neurological disorders. At the same time, startups are emerging, investors are pouring money into the space and companies are accelerating their development programs. After decades of clinical research and false starts, are BCI systems finally here? http://www.bioworld.com/articles/732045 Mon, 22 Jun 2026 11:00:00 -0400 https://www.bioworld.com/articles/732045-have-brain-computer-interfaces-finally-arrived Blue brain with computer chip MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan. http://www.bioworld.com/articles/732090 Mon, 22 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732090-k2-nabs-two-antengene-bispecific-tces-in-2b-license-option-deal Photo of two people shaking hands near lab equipment Schizophrenia (SZ), bipolar disorder (BP), major depression (MDD) and autism spectrum disorder (ASD) are serious mental illnesses (SMIs) that affect a significant proportion of the worldwide population. Large genome-wide association studies have pointed to overlapping genetics including both common and rare variants as cause of these SMIs. A recent study published on June 16, 2026, in Genomic Psychiatry has shed some light regarding the etiology of SMIs. Genomic Psychiatry has shed some light regarding the etiology of SMIs.]]> http://www.bioworld.com/articles/732007 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732007-family-genomics-reveals-shared-roots-of-mental-illness Concept art for genetic diversity. On the eve of the June 17 Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, which will discuss Moderna Inc.’s mRNA-1010, researchers at Washington University School of Medicine in St. Louis have reported that the vaccine conferred broader and more durable protection than a standard flu shot. http://www.bioworld.com/articles/731989 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731989-mrna-flu-vaccine-can-activate-broad-germinal-center-response mRNA vaccines are composed of messenger RNA encapsulated in lipid nanoparticles Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment could occur on an outpatient basis. http://www.bioworld.com/articles/731988 Tue, 16 Jun 2026 11:00:00 -0400 https://www.bioworld.com/articles/731988-viva-in-vivo-at-eha-in-vivo-car-t-data-continues-to-impress CAR T and red blood cells Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable feature of aging. Certainly, it is near universal in those older than 60. CH is not itself a disease, but 1%-2% of CH cases progress to acute myeloid leukemia, and it raises the risk of some other types of cancer as well. A total of eight genes are responsible for 95% of CH cases, George Vassiliou told the audience in Saturday’s plenary session at the 2026 Annual Congress of the European Hematology Association (EHA 2026). http://www.bioworld.com/articles/731978 Tue, 16 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731978-for-clonal-hematopoiesis-epigenetics-can-be-in-drivers-seat Red blood cells, DNA Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on the GLP-1 receptor but instead on the gut microbiota, since the treatment increases the presence of the bacterium Lactobacillus delbrueckii. Lactobacillus delbrueckii. ]]> http://www.bioworld.com/articles/731977 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731977-microbiota-modulates-the-antidepressant-effects-of-glp-1-analogues Illustration of Lactobacillus Lactobacillus Treatment with first-generation CAR T cells regularly sent patients to the intensive care unit. Now, investigators are envisioning a future where CAR T treatment could occur on an outpatient basis. At Sunday’s late-breaking oral session of the 2026 Annual Congress of the European Hematology Association (EHA2026), Lei Fan told his audience that the first-in-human data “support further development of LB-2501 as a potential first-in-class, off-the-shelf, single infusion, no lymphodepletion, outpatient use CAR T therapy.” Fan is a professor of hematology at the First Affiliated Hospital of Nanjing Medical University. http://www.bioworld.com/articles/731976 Sun, 14 Jun 2026 11:00:00 -0400 https://www.bioworld.com/articles/731976-viva-in-vivo-at-eha-in-vivo-car-t-data-continues-to-impress CAR T and red blood cells In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into cancer cells,” Franck Bourdeaut told his audience at the 2026 Annual Congress of the European Hematology Association (EHA 2026). “On the contrary, in pediatric cancers, it is assumed that very few mutations are responsible for a maturation block, make these cells derail from their normal differentiation trajectory and ultimately result in an early onset typical pediatric cancer.” http://www.bioworld.com/articles/731957 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731957-eha-2026-with-new-lenses-a-changing-view-on-pediatric-cancers Genome sequence map Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an editorial published in its flagship journal Diabetes Care at the ADA’s meeting in New Orleans last Friday. Diabetes Care at the ADA’s meeting in New Orleans last Friday.]]> http://www.bioworld.com/articles/731723 Wed, 10 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731723-researchers-hit-back-after-colleagues-removed-from-ada-meeting Hands holding paper Scientists at Columbia University have used base editing to make precise changes in the genomes of human embryos, avoiding the damage to chromosomes that occurs following two-stranded DNA cuts with conventional Crispr-Cas9 editing. http://www.bioworld.com/articles/731708 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731708-columbia-researchers-use-base-editing-to-modify-human-embryo-genome DNA double helix under a magnifying glass Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help identify people who could benefit from preventive drugs. Published in Cell, the study was a collaboration between the Francis Crick Institute and University College London. It was co-led by Walter and Eliza Hall Institute laboratory head Clare Weeden, who conducted the research while at the Crick. Cell, the study was a collaboration between the Francis Crick Institute and University College London. It was co-led by Walter and Eliza Hall Institute laboratory head Clare Weeden, who conducted the research while at the Crick.]]> http://www.bioworld.com/articles/731757 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731757-pre-disease-plasma-signature-may-help-redefine-lung-cancer-risk Blood sample tubes after centrifuge Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The scientific community has explored small molecules, antibodies and nanobodies to develop ligands. Skape Bio Inc. is betting on creating miniproteins, a strategy that brings precise solutions for different functions. http://www.bioworld.com/articles/731737 Mon, 08 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731737-skape-bio-unlocks-gpcr-targets-with-de-novo-designed-miniproteins 3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane. β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane. TRIM21, an enzyme involved in intracellular substrate degradation, can recognize viruses and bacteria that enter the cytosol when they are coated with antibodies. Just as it tags complex molecules for elimination, it can direct these infectious microorganisms to lysosomes through a mechanism its discoverers have termed antibody-directed xenophagy (ADX). Scientists at the Medical Research Council (MRC) Laboratory of Molecular Biology (LMB) in Cambridge, U.K., have identified the genes involved in this antibody-dependent degradation pathway, which acts as an antimicrobial process, and reported their findings in Molecular Cell on June 4, 2026. Molecular Cell on June 4, 2026.]]> http://www.bioworld.com/articles/731671 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731671-trim21-marks-viruses-and-bacteria-for-degradation-via-autophagy 3D illustration showing fusion of lysosome with autophagosome containing microbes and molecules Autophagy The microbiome and a frontline innate antimicrobial sensor, Toll-like receptor 5 (TLR5), play an essential role in the development of idiopathic pulmonary fibrosis (IPF). A scientific collaboration led by researchers at the National Institute of Environmental Health Sciences has revealed how TLR5 protects against fibrosis through its ability to modulate the lung microbiome. Their study also shows that activating TLR5 protects against fibrosis and corrects pulmonary dysbiosis. http://www.bioworld.com/articles/731651 Thu, 04 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731651-innate-immunity-and-microbiome-allied-against-pulmonary-fibrosis Illustration of therapies for lung diseases Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types. http://www.bioworld.com/articles/731544 Wed, 03 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731544-technique-links-non-coding-mutations-to-disease-genes-they-regulate Gastrointestinal system with DNA, scientific background Shiga toxin-producing Escherichia coli (STEC) represents a public health threat that can lead to serious problems, such as bloody diarrhea and hemolytic uremic syndrome in children in up to 10%-15% of cases. Antibiotics that normally combat diarrhea are not recommended for STEC infections and patients are usually treated only for symptomatology. Now, French researchers from Eligo Bioscience SA and their collaborators have published a paper on a CRISPR-based antimicrobial approach, EB-003. Escherichia coli (STEC) represents a public health threat that can lead to serious problems, such as bloody diarrhea and hemolytic uremic syndrome in children in up to 10%-15% of cases. Antibiotics that normally combat diarrhea are not recommended for STEC infections and patients are usually treated only for symptomatology. Now, French researchers from Eligo Bioscience SA and their collaborators have published a paper on a CRISPR-based antimicrobial approach, EB-003.]]> http://www.bioworld.com/articles/731670 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731670-crispr-based-approach-fights-pathogenic-eme-coli-em Illustration of E. coli with window showing DNA E.coli. Credit: Thom Leach. License: CC by SA